Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to people with visual disabilities who are using a screen reader; Press Control-F10 to open an accessibility menu.

Novel Therapeutic Perspectives in the Management of DLBCL: The Role of Antibody-Drug Conjugates and Bispecific Antibodies

Tuesday, June 21, 2022

6:00PM – 7:00PM ET

Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.

PROGRAM OVERVIEW

This Community Whiteboard ECHO Series and Online Enduring activity is designed to increase the multi-disciplinary oncology care team recognition of the role of targeted and bispecific antibodies in management of relapsed/refractory DLBCL; strengthen their understanding of clinical trial outcomes and adverse events with targeted and bispecific antibodies; and improve their awareness of multidisciplinary best practices for managing adverse events from targeted therapies.

Presenting Faculty:
P. Connor Johnson, MD
Attending Oncologist, Center for Lymphoma, Massachusetts General Hospital
Instructor of Medicine, Harvard Medical School
Boston, MA

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Evaluate novel targets in the management of diffuse large B-cell lymphoma (DLBCL).
  • Analyze the outcomes of key trials in DLBCL management, including ongoing trials of novel therapies for the management of relapsed/refractory disease.
  • Recognize potential adverse events associated with novel therapies for DLBCL management and best practices for multidisciplinary management.

Target Audience

This activity is designed to meet the educational needs of community-based medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with DLBCL.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com